A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

June 1, 2026 updated by: Deciphera Pharmaceuticals, LLC

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
94

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Denmark
      • Aarhus, Denmark, 8200
        • Recruiting
        • Aarhus University Hospital
        • Contact:
        • Principal Investigator:
          • Ninna Aggerholm Pedersen, MD
  • France
      • Lille, France, 59020
        • Recruiting
        • Centre Oscar Lambret
        • Principal Investigator:
          • Loic Lebellec, MD
        • Contact:
      • Paris, France, 75015
        • Recruiting
        • Hôpital Européen Georges Pompidou
        • Contact:
          • Phone Number: +33156092802
        • Principal Investigator:
          • Widad Lahlou, MD
  • Germany
      • Frankfurt, Germany, 60590
        • Recruiting
        • Universitatsklinikum Franfurt
        • Contact:
        • Principal Investigator:
          • Marit Ahrens, MD
      • Hamburg, Germany, 20246
        • Recruiting
        • Universitätsklinikum Eppendorf
        • Contact:
        • Principal Investigator:
          • Jana Striefler, MD
  • Italy
      • Florence, Italy, 50134
        • Recruiting
        • AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial
        • Principal Investigator:
          • Lorenzo Antonuzzo, MD
        • Contact:
      • Genova, Italy, 16132
        • Recruiting
        • IRCCS Azienda Ospedaliera Metropolitana
        • Contact:
        • Principal Investigator:
          • Danila Comandini, MD
      • Milan, Italy, 20141
        • Recruiting
        • Istituto Europeo di Oncologia
        • Principal Investigator:
          • Elisabetta Setola, MD
        • Contact:
  • Netherlands
      • Amsterdam, Netherlands, 1066 CX
        • Recruiting
        • Antonie Van Leeuwenhoek Hospital
        • Principal Investigator:
          • Neeltje Steeghs, MD
        • Contact:
          • Phone Number: +31205122103
      • Nijmegen, Netherlands, 6525GA
        • Recruiting
        • Radboudumc
        • Principal Investigator:
          • Ingrid Desar, MD
        • Contact:
          • Phone Number: +31 (0)6 3113 6977
  • Portugal
      • Porto, Portugal, 4200-072
        • Recruiting
        • Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E.
        • Contact:
        • Principal Investigator:
          • Miguel Abreu, MD
  • Spain
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramón y Cajal
        • Principal Investigator:
          • Maria Angeles Vaz Salgado, MD
        • Contact:
      • Madrid, Spain, 28040
        • Recruiting
        • Hospital Universitario Clínico San Carlos
        • Contact:
        • Principal Investigator:
          • Gloria Marquina Ospina, MD
      • Seville, Spain, 41013
        • Recruiting
        • Hospital Universitario Virgen del Rocio
        • Contact:
        • Principal Investigator:
          • Maria Pilar Sancho Marquez, MD
  • Switzerland
      • Bern, Switzerland, 3010
        • Recruiting
        • Inselspital Universitätsklinikum Bern
        • Principal Investigator:
          • Attila Kollar, MD
  • United States
    • California
      • Los Angeles, California, United States, 90033
        • Recruiting
        • University of Southern California - Norris Comprehensive Cancer Center
        • Principal Investigator:
          • Syma Iqbal, MD
        • Contact:
      • Los Angeles, California, United States, 90095
        • Recruiting
        • UCLA Department of Medicine-Hematology/Oncology
        • Contact:
        • Principal Investigator:
          • Arun Singh, MD
    • Florida
      • Miami, Florida, United States, 33136
        • Recruiting
        • Sylvester Comprehensive Cancer Center
        • Contact:
        • Principal Investigator:
          • Jonathan C Trent, MD, PhD
    • Massachusetts
      • Worcester, Massachusetts, United States, 01655
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • START Midwest
        • Contact:
        • Principal Investigator:
          • Sreenivasa Chandana, M.D., Ph.D.
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine - Siteman Cancer Center
        • Principal Investigator:
          • Mia Weiss, MD
        • Contact:
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center - Main Campus
        • Principal Investigator:
          • Ping Chi, MD, PhD
        • Contact:
        • Contact:
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic Taussig Cancer Center
        • Contact:
    • Oregon
      • Portland, Oregon, United States, 97239
        • Recruiting
        • Oregon Health & Science University
        • Contact:
          • Knight Cancer Institute Clinical Trials
          • Phone Number: 503-494-1080
          • Email: trials@ohsu.edu
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19111
        • Recruiting
        • Fox Chase Cancer Center
        • Principal Investigator:
          • Margaret von Mehren, MD
        • Contact:
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Virginia Cancer Specialist, PC
        • Contact:
        • Principal Investigator:
          • Chao Yin, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female ≥18 years of age
  • Module A: Part 1 and Part 2:

Module A Part 1 and Part 2 inlexisertib combination closed on January 8, 2024, with no participants enrolled.

  • Module B: Only for Part 1 (Safety/Dose-finding):

    • Pathologically confirmed diagnosis of GIST with a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation
    • Must have progressed on at least one approved systemic regimen given in the locally advanced or metastatic setting or have documented intolerance to it
    • Must not have received prior ripretinib treatment

  • Module B: Only for Part 2 (Expansion)

    • Pathologically confirmed GIST with documented mutation in KIT exon 11
    • Must have progressed on imatinib given in the locally advanced or metastatic setting or have been intolerant to imatinib and may not have received additional systemic therapy for GIST
  • Must have at least 1 measurable lesion according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
  • Must have a life expectancy of more than 3 months and an ECOG performance status of 0-1
  • Adequate organ function and bone marrow reserve based on laboratory assessments performed at Screening
  • Must provide a fresh tumor biopsy, if able

Exclusion Criteria:

  • Must not have received the following within the specified time periods prior to the first dose of study drug:

    1. Medications, including anticancer therapies, that are known strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp) including certain herbal medications (eg, St. John's wort): 14 days or 5×the half-life of the medication (whichever is longer)
    2. Other anticancer therapies and any investigational therapies with a known safety and PK profile: 14 days or 5×the half-life of the medication (whichever is shorter)
    3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days
    4. Grapefruit or grapefruit juice: 14 days
  • Have not recovered from all clinically relevant toxicities from prior therapy
  • New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug
  • Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease
  • Malabsorption syndrome
  • Radiation for indications other than bone disease must have been completed 4 weeks prior to first dose of study drug, unless it consisted of limited field palliative radiation, including whole brain radiation, which must have been completed at least 2 weeks prior to first dose of study drug
  • Major surgery within 4 weeks of the first dose of study drug
  • Active HIV, Hepatitis B or Hepatitis C infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Dose Escalation (Part 1, Module A)
Escalation Module A Part 1 inlexisertib combination closed on January 8, 2024, with no participants enrolled.
Drug: Inlexisertib
Oral Tablet Formulation
Other Names:
  • DCC-3116
Experimental: Expansion (Part 2, Module A)
Expansion Module A Part 2 inlexisertib combination closed on January 8, 2024, with no participants enrolled.
Drug: Inlexisertib
Oral Tablet Formulation
Other Names:
  • DCC-3116
Experimental: Dose Escalation (Part 1, Module B)
Inlexisertib tablets in escalating dose cohorts in 28-day cycles will be administered in combination with ripretinib once daily (QD).
Drug: Ripretinib
Oral Tablet Formulation
Other Names:
  • QINLOCK, DCC-2618
Drug: Inlexisertib
Oral Tablet Formulation
Other Names:
  • DCC-3116
Experimental: Expansion (Part 2, Module B)
Inlexisertib tablets will be administered in combination with ripretinib in 28-day cycles to evaluate preliminary efficacy in participants with 2nd-line advanced gastrointestinal stromal tumor (GIST).
Drug: Ripretinib
Oral Tablet Formulation
Other Names:
  • QINLOCK, DCC-2618
Drug: Inlexisertib
Oral Tablet Formulation
Other Names:
  • DCC-3116

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR) (Expansion Phase)
Time Frame: Approximately 24 months
Proportion of participants who achieve CR or PR per histology-specific consensus response criteria.
Approximately 24 months
Incidence of Adverse Events (Escalation Phase)
Time Frame: Approximately 24 months
Identify the observed adverse events and serious adverse events associated with inlexisertib in combination with other anticancer therapies.
Approximately 24 months
Recommended Phase 2 Doses (RP2D) (Escalation Phase)
Time Frame: Approximately 18 months
Identify the dose-limiting toxicities for each dose level tested and determine the recommended Phase 2 doses of inlexisertib in combination with other anticancer therapies.
Approximately 18 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: Approximately 48 months
OS is defined as the time from initiation of treatment until death.
Approximately 48 months
Duration of response (DoR)
Time Frame: Approximately 24 months
DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) per histology-specific consensus response criteria until the first date that the progressive disease is objectively documented or death, whichever occurs first.
Approximately 24 months
Disease Control Rate (DCR)
Time Frame: Approximately 24 months
The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD) per histology-specific consensus response criteria.
Approximately 24 months
Time to response
Time Frame: Approximately 24 months
Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per histology-specific consensus response criteria.
Approximately 24 months
Progression-free survival (PFS)
Time Frame: Approximately 24 months
PFS is defined as the time from initiation of treatment until documented disease progression per histology-specific consensus response criteria or death, whichever occurs first.
Approximately 24 months
Maximum observed concentration (Cmax)
Time Frame: Predose and up to 12 hours postdose
Measure the maximum observed concentration of inlexisertib combinations.
Predose and up to 12 hours postdose
Time to maximum observed concentration (Tmax)
Time Frame: Predose and up to 12 hours postdose
Measure the time to maximum plasma concentration of inlexisertib combinations.
Predose and up to 12 hours postdose
Minimum observed concentration (Cmin)
Time Frame: Predose and up to 12 hours postdose
Measure the minimum observed concentration of inlexisertib combinations.
Predose and up to 12 hours postdose
Area under the concentration-time curve (AUC)
Time Frame: Predose and up to 12 hours postdose
Measure the AUC of inlexisertib combinations.
Predose and up to 12 hours postdose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Deciphera Pharmaceuticals, LLC

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Pfizer

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Team, Deciphera Pharmaceuticals, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 28, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 14, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 14, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 24, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 2, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DCC-3116-01-002
  • 2024-516476-15-00 (Ctis)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on GIST

Clinical Trials on Ripretinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings